Aptargroup Inc
Packaging
Aptargroup Inc (ATR) Stock News
The latest ATR headlines and market coverage — 9 recent stories, updated throughout the day.
- Benzinga·
ATRenew Posts Record Q1 Profit, Fastest Revenue Growth In 3 Years
The company recorded its fastest revenue growth in nearly three years in the first quarter, as it stepped up a campaign to sell more of its recycled products directly to consumers image credit: Bamboo Works Key Takeaways: ATRenew's revenue rose 32.4% in the first quarter, its fastest rate in nearly three years, as it posted a record non-GAAP profit for the period The recycler is boosting its margins by doing more direct recycling and reselling, with direct sales to consumers accounting for nearly half of its product sales A growing focus on precision trade-in scenarios to boost recycling and improve its operating efficiency is propelling ATRenew Inc. (NYSE: RERE ) to some of its strongest revenue growth in years and record profits, according to its latest quarterly results released on May 19. Founded in 2011, ATRenew spent its early years honing its abilities to collect and sell used goods, with a special focus on smartphones. As it built up its business, it increasingly focused on boosting efficiency and profitability, taking steps like increasing higher-margin product compliant refurbishment over simply reselling recycled phones. The company also discovered it could leverage its brand as a top recycler into other product categories outside its original electronics, and today also offers recycling in other areas like gold, luxury bags and even vintage liquors. Those efforts lifted the company to its first net profit in 2023, followed by its first operating profit in 2024. Since then, ATRenew has consistently reported new records for both of those profit metrics, including its latest non-GAAP net profit of 140.1 million yuan ($20.6 million) in the first quarter, up 79.6% from 78 million yuan a year earlier. Its quarterly non-GAAP income from operations rose 70.2% to 190.5 million yuan. Those gains were facilitated partly by higher margins, with ATRenew reporting
- Benzinga·
ATRenew Reports Strong Q1 Results As Direct Retail, Trade-In Volumes Surge
Shares of ATRenew Inc (NYSE: RERE ) came under pressure in early trading on Wednesday, after rallying almost 12% follow the release of the company's first-quarter results . The leading player in China's circular economy reported strong growth in both revenue and profitability, crediting its performance to a strategic shift toward direct-to-consumer retail and the continued expansion of its trade-in services. Revenue And Profit Growth Total revenue for the quarter reached RMB 6.16 billion ($903.89 million), up 32.4% year-on-year, surpassing the high end of the company's guidance. This growth was driven mainly by product sales, which climbed 34.4% to RMB 5.73 billion ($840.79 million). Non-GAAP operating profit grew 70.2% to RMB 190 million ($27.88 million). The company's non-GAAP operating profit margin expanded to 3.1%, from 2.4% in the year-ago quarter. Shift To Direct Retail ATRenew's results were boosted by its "1P-centric" (first-party-centric) strategy, ... Full story available on Benzinga.com
- GlobeNewswire Inc.·
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
A securities class action lawsuit has been filed against Atara Biotherapeutics for allegedly making false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that undermined FDA approval prospects for tabelecleucel. Investors who purchased securities between May 20, 2024 and January 9, 2026 may be eligible for compensation. The lead plaintiff deadline is May 22, 2026.
- Benzinga·
ATRenew Inc. Reports Unaudited First Quarter 2026 Financial Results
<p xmlns="http://www.w3.org/1999/xhtml" id="temp_ReleaseStart"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SHANGHAI</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 19, 2026</span> /PRNewswire/ -- ATRenew Inc. (&#34;ATRenew&#34; or the &#34;Company&#34;) (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/RERE" rel="nofollow">RERE</a>), a pioneer in technology-driven recycling and trade-in solutions for consumer products in China, today announced its unaudited financial results for the three months ended March 31, 2026.</p> <p xmlns="http://www.w3.org/1999/xhtml" class="prntal"><b xmlns="http://www.w3.org/1999/xhtml">First Quarter 2026 Highlights</b></p> <ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Total net revenues</b> grew by 32.4% to RMB6,160.1 million (US$893.0 million) from RMB4,653.5 million in the same period of 2025.</li> <li xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Income from operations </b>increased by 154.9% to RMB185.3 million (US$26.9 million) from RMB72.7 million in the same period of 2025. <b xmlns="http://www.w3.org/1999/xhtml">Adjusted income from operations (non-GAAP)<sup xmlns="http://www.w3.org/1999/xhtml">[1]</sup> </b>grew by 70.2% to RMB190.5 million (US$27.6 million) from RMB111.9 million in the same period of 2025.</li> <li xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http
- GlobeNewswire Inc.·
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.
- GlobeNewswire Inc.·
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is seeking investors to join a class action lawsuit against Atara Biotherapeutics for alleged securities fraud. The company allegedly made false and misleading statements regarding manufacturing problems and deficiencies in its ALLELE study for tabelecleucel, overstating the drug's prospects and concealing regulatory risks. Investors who purchased securities between May 20, 2024 and January 9, 2026 are encouraged to participate.
- GlobeNewswire Inc.·
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Atara Biotherapeutics faces a class action securities fraud lawsuit after the FDA rejected its Epstein-Barr virus treatment (tabelecleucel/EBVALLO) twice due to manufacturing issues and inadequate trial design. The stock plummeted 40.5% on January 16, 2025, and another 57% on January 12, 2026, following the rejections. Shareholders who purchased ATRA securities between May 20, 2024 and January 9, 2026 are urged to file lead plaintiff motions by May 22, 2026.
- GlobeNewswire Inc.·
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Rosen Law Firm is soliciting investors in Atara Biotherapeutics who purchased securities between May 20, 2024 and January 9, 2026 to join a class action lawsuit. The lawsuit alleges that Atara made false statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, and that regulatory prospects were overstated. The lead plaintiff deadline is May 22, 2026.
- GlobeNewswire Inc.·
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA
Levi & Korsinsky announces a class action securities lawsuit against Atara Biotherapeutics for alleged fraud between May 20, 2024 and January 9, 2026. The complaint alleges the company made false statements about manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, while overstating regulatory prospects. Investors who suffered losses during this period can request lead plaintiff status by May 22, 2026.